These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38557814)

  • 21. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polypill Better for Secondary Cardiovascular Prevention Than Physician-Directed Care.
    Ebell MH
    Am Fam Physician; 2023 Mar; 107(3):318-319. PubMed ID: 36920802
    [No Abstract]   [Full Text] [Related]  

  • 23. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.
    Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C
    Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
    Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J
    Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars).
    Malekzadeh F; Gandomkar A; Poustchi H; Etemadi A; Roshandel G; Attar A; Abtahi F; Sadeghi Boogar S; Mohammadkarimi V; Fattahi MR; Mohagheghi A; Malekzadeh R; Sepanlou SG
    Heart; 2024 Jun; 110(14):940-946. PubMed ID: 38485210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A SECURE polypill as a strategy at the heart of secondary prevention.
    Liuzzo G; Patrono C
    Eur Heart J; 2022 Nov; 43(43):4534-4535. PubMed ID: 36148477
    [No Abstract]   [Full Text] [Related]  

  • 32. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
    Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
    Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
    López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
    Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fixed-dose combination treatment after stroke for secondary prevention in China: a national community-based study.
    Longde W; Ling Y; Yang H; Yi Z; Yongjun W; Xunming J; Xiaoyuan N; Qiumin Q; Li H; Yuming X; Mei L; Jiayi S; Jing L; Dong Z
    Stroke; 2015 May; 46(5):1295-300. PubMed ID: 25782466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
    Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
    Trials; 2011 Jan; 12():3. PubMed ID: 21205325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The polypill in cardiovascular prevention: evidence, limitations and perspective - position paper of the European Society of Hypertension.
    Coca A; Agabiti-Rosei E; Cifkova R; Manolis AJ; Redón J; Mancia G
    J Hypertens; 2017 Aug; 35(8):1546-1553. PubMed ID: 28448291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined use of polypill components in patients with type 2 diabetes mellitus.
    Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
    Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
    Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
    N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The strong case for government funding of a polypill for the secondary prevention of cardiovascular disease in New Zealand.
    Selak V; Bullen C; Arroll B; Doughty R; Doughty R; Grey C; Harwood M; Crengle S
    N Z Med J; 2019 Sep; 132(1502):77-83. PubMed ID: 31563929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials.
    Rivera A; Campos B; Ceolin S; Godoi A; Castanha E; Campello Jorge CA; Cardoso R
    Eur J Prev Cardiol; 2023 Nov; 30(16):1828-1837. PubMed ID: 37490769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.